RESUMO

BACKGROUND AND AIMS: Pirfenidone (PFD), an oral antifibrotic drug, has been authorized by the EMA and FDA for treatment of idiopathic pulmonary fibrosis. Few studies have addressed its use in advanced liver fibrosis (ALF). We evaluated a prolonged-release formulation (PR-PFD) plus standard of care on disease progression in ALF. METHODS: 281 ALF patients from 12 centers receiving PR-PFD (600 mg bid) were screened; 122 completed 1 year of treatment. Additionally, 74 patients received only standard of care regimen. Average age was 64 ± 12 years, 58% female. 43.5% had fatty liver disease (NAFLD), 22.5% viral hepatitis C (VHC), 17% autoimmune hepatitis (AIH), and 17% alcoholic liver disease (ALD). Baseline fibrosis was F4 in 74% and F3 in 26%. Antifibrotic effects were assessed by transient elastography (Fibroscan®) and Fibro Test® (FT); Cytokines and PFD plasma levels were tracked and quality of life evaluated. RESULTS: We found a significant reduction in fibrosis in 35% of PR-PFD patients and only in 4.1% in non PR-PFD patients. Child-Pugh score improved in 29.7%. Biochemical values remained stable; 40.6% and 43.3% decreased ALT or AST, respectively. TGFß1 (pg/mL) levels were lower in PFD-treated patients. PFD serum concentration (µg/mL) was higher (8.2 ± 1.7) in fibrosis regression profile (FRP) patients compared to fibrosis progression profile (FPP) patients (4.7 ± 0.3 µg/mL, p < 0.01). 12% reported transient burning or nausea and 7% photosensitivity. Quality of life (Euro-Qol scale) improved from 62 ± 5 to 84 ± 3 (p < 0.001) and from 32 ± 3 to 42 ± 2 (p < 0.008) (FACIT scale). CONCLUSIONS: PR-PFD is efficacious and safe in ALF and associated with promising antifibrotic effects. TRIAL REGISTRATION: Clinical trial number: NCT04099407.

Assuntos

Cirrose Hepática , Hepatopatias , Fígado , Piridonas , Qualidade de Vida , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/efeitos adversos , Preparações de Ação Retardada/administração & dosagem , Preparações de Ação Retardada/efeitos adversos , Progressão da Doença , Técnicas de Imagem por Elasticidade/métodos , Feminino , Humanos , Fígado/diagnóstico por imagem , Fígado/patologia , Cirrose Hepática/diagnóstico , Cirrose Hepática/tratamento farmacológico , Cirrose Hepática/etiologia , Cirrose Hepática/psicologia , Hepatopatias/classificação , Hepatopatias/complicações , Hepatopatias/diagnóstico , Masculino , Pessoa de Meia-Idade , Estudo de Prova de Conceito , Piridonas/administração & dosagem , Piridonas/efeitos adversos , Padrão de Cuidado , Resultado do Tratamento

RESUMO

BACKGROUND & AIMS: Several studies have reported that low doses of interferon can delay the development of hepatocellular carcinoma (HCC) and progression of chronic hepatitis C. We investigated the incidence of clinical events among participants of the Evaluation of PegIntron in Control of Hepatitis C Cirrhosis (EPIC)3 program. METHODS: Data were analyzed from an open-label randomized study of patients with chronic hepatitis C who had failed to respond to interferon alfa plus ribavirin. All patients had compensated cirrhosis with no evidence of HCC. Patients received peginterferon alfa-2b (0.5 µg/kg/week; n=311) or no treatment (controls, n=315) for a maximum period of 5 years or until 98 patients had a clinical event (hepatic decompensation, HCC, death, or liver transplantation). The primary measure of efficacy was time until the first clinical event. RESULTS: There was no significant difference in time to first clinical event among patients who received peginterferon alfa-2b compared with controls (hazard ratio [HR], 1.452; 95% confidence interval [CI]: 0.880-2.396). There was no decrease in the development of HCC with therapy. The time to disease progression (clinical events or new or enlarged varices) was significantly longer for patients who received peginterferon alfa-2b compared with controls (HR, 1.564; 95% CI: 1.130-2.166). In a prospectively defined subanalysis of patients with baseline portal hypertension, peginterferon alfa-2b significantly increased the time to first clinical event compared with controls (P=.016). There were no new safety observations. CONCLUSIONS: Maintenance therapy with peginterferon alfa-2b is not warranted in all patients and does not prevent HCC. However, there is a potential clinical benefit of long-term suppressive therapy in patients with preexisting portal hypertension.

Assuntos

Antivirais/administração & dosagem , Carcinoma Hepatocelular/prevenção & controle , Hepatite C Crônica/tratamento farmacológico , Interferon-alfa/administração & dosagem , Cirrose Hepática/tratamento farmacológico , Neoplasias Hepáticas/prevenção & controle , Polietilenoglicóis/administração & dosagem , Antivirais/efeitos adversos , Biomarcadores/sangue , Carcinoma Hepatocelular/mortalidade , Carcinoma Hepatocelular/virologia , Progressão da Doença , Esquema de Medicação , Europa (Continente) , Feminino , Hepacivirus/genética , Hepatite C Crônica/complicações , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/mortalidade , Humanos , Hipertensão Portal/tratamento farmacológico , Hipertensão Portal/virologia , Interferon alfa-2 , Interferon-alfa/efeitos adversos , Estimativa de Kaplan-Meier , Cirrose Hepática/diagnóstico , Cirrose Hepática/mortalidade , Cirrose Hepática/virologia , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/virologia , Masculino , Pessoa de Meia-Idade , América do Norte , Seleção de Pacientes , Polietilenoglicóis/efeitos adversos , Modelos de Riscos Proporcionais , Estudos Prospectivos , RNA Viral/sangue , Proteínas Recombinantes , Medição de Risco , Fatores de Risco , América do Sul , Fatores de Tempo , Resultado do Tratamento , Carga Viral

RESUMO

BACKGROUND: Levofloxacin is a synthetic fluoroquinolone with a broad spectrum of antibacterial activity. It is indicated for the treatment of respiratory, sinus, skin, and urinary tract infections. Although generic formulations of oral levofloxacin are marketed in Mexico, a literature search did not identify published data concerning the bioavailability of these formulations; these data would be relevant to secure marketing of a test formulation in Mexico. OBJECTIVE: The aim of this study was to compare the bioavailability and determine the bioequivalence of a test formulation (an oral tablet containing levofloxacin 500 mg) with its corresponding listed reference-drug formulation in Mexico (a list issued by Mexican Health Authorities). METHODS: A single-dose, open-label, randomized-sequence, 2-period crossover design was used in this study. Eligible participants were healthy Mexican adults of either sex, randomly assigned to receive the test formulation followed by the corresponding reference formulation, or vice versa, with a 1-week washout period between doses. After a 10-hour overnight fast, the participants received the assigned formulation. Plasma concentrations of levofloxacin were determined using high-performance thin-layer chromatography, and densitometric analysis was performed at 300 nm. For the analysis of pharmacokinetic parameters, including C(max), AUC0(-24), and AUC(0-infinity)), blood samples were drawn at baseline and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours after administration. The test formulation was considered to meet the criteria for bioequivalence if the geometric mean ratios (test/reference) were with- in the predetermined range of 80% to 125%. Tolerability was determined by clinical assessment, vital signs, laboratory analysis, and interviews with participants about adverse events. RESULTS: A total of 26 participants were enrolled, including 14 men and 12 women with a mean (SD) age of 24 (4) years (range, 18-34 years), weight of 62.2 (10.0) kg (range, 45.5-80.0 kg), height of 163 (9) cm (range, 148-176 cm), and body mass index of 23.3 (2.4) kg/m(2) (range, 19.2-27.1 kg/m(2)). The 90% CIs for log-transformed C(max), AUC(0-24), and AUC(0-infinity) were 94.48% to 106.22%, 90.01% to 116.44%, and 85.11% to 114.00%, respectively. Eleven participants reported a total of 20 adverse events during the study. None of the adverse events were considered serious. CONCLUSIONS: In this small study in healthy, fasting Mexican adults, a single 500-mg dose of the test formulation of orally administered levofloxacin met the regulatory requirements to assume bioequivalence based on the rate and extent of absorption. Both formulations were well tolerated.

Assuntos

Antibacterianos/farmacocinética , Levofloxacino , Ofloxacino/farmacocinética , Administração Oral , Adolescente , Adulto , Antibacterianos/administração & dosagem , Antibacterianos/efeitos adversos , Área Sob a Curva , Disponibilidade Biológica , Cromatografia em Camada Fina/métodos , Estudos Cross-Over , Densitometria , Feminino , Humanos , Masculino , México , Ofloxacino/administração & dosagem , Ofloxacino/efeitos adversos , Comprimidos , Equivalência Terapêutica , Fatores de Tempo , Adulto Jovem

RESUMO

BACKGROUND: Ketorolac tromethamine (ie, ketorolac) is an NSAID that appears to have several mechanisms of action, including inhibition of prostaglandin synthesis, modulatory effect on opioid receptors, and nitric oxide synthesis. Ketorolac is used in the treatment of pain. There are various generic formulations of sublingual ketorolac available in Mexico. However, a literature search did not identify published data concerning the bioavailability of these formulations in the Mexican population. OBJECTIVE: The aim of this study was to compare the bioavailability of 2 sublingual formulations of ketorolac 30-mg tablets in healthy Mexican adult volunteers. METHODS: This was a randomized-sequence, open-label, single-dose, 2-period crossover (2 dosing periods x 2 treatments) study comparing the bioavailability of two 30-mg sublingual tablet formulations of ketorolac. Healthy Mexican adult (aged, 18-55 years) men and women were eligible for inclusion. Subjects were randomly assigned in a 1:1 ratio to receive a single dose of the test formulation or the reference formulation. After a 12-hour overnight fast, subjects received a single dose of the corresponding formulation. There was a 7-day washout period between administration periods. Plasma samples were obtained over a 24-hour period after administration. Plasma ketorolac concentrations were analyzed by high-performance liquid chromatography for analysis of pharmacokinetic properties, including Cmax, AUC0-24, and AUC0-infinity. Blood samples were drawn immediately after sublingual placement of the drug and at 10, 20, 30, 40, 50, 60, 75, and 90 minutes and 2, 4, 6, 8, 10, 12, and 24 hours after dosing. The formulations were considered bioequivalent if the geometric mean ratios of Cmax and AUC were within the predetermined range of 80% to 125% and if P for the 90% CIs was <0.05. Tolerability was assessed by vital sign monitoring, laboratory analysis results, and subject interviews. RESULTS: A total of 27 subjects (18 women, 9 men; mean [SD] age, 27 [9] years [range, 18-47 years]; weight, 61 [8] kg [48-79 kg]; height, 163 [8] cm [150-180 cm]) were enrolled and completed the study. Fourteen subjects received the test formulation first. No period or sequence effect was observed. The 90% CIs for the corresponding differences in natural log Cmax, AUC0-24, and AUC0-infinity were 95.94% to 114.66%, 98.34% to 105.90%, and 99.25% to 108.36%, respectively (all, (P) < 0.05), meeting the predetermined criteria for bioequivalence. Sixteen subjects experienced a total of 20 adverse events (AEs) during the study. None of the AEs were considered serious. One AE (nausea) appeared to be related to use of the reference formulation. CONCLUSIONS: In this small study in 27 healthy Mexican adult volunteers, the test formulation of a single, 30-mg sublingual tablet of ketorolac appeared to be bioequivalent to the reference formulation based on the rate and extent of absorption. Both formulations were well tolerated.

Assuntos

Anti-Inflamatórios não Esteroides/farmacocinética , Cetorolaco de Trometamina/farmacocinética , Administração Sublingual , Adolescente , Adulto , Análise de Variância , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/efeitos adversos , Área Sob a Curva , Disponibilidade Biológica , Cromatografia Líquida de Alta Pressão , Estudos Cross-Over , Feminino , Humanos , Cetorolaco de Trometamina/administração & dosagem , Cetorolaco de Trometamina/efeitos adversos , Masculino , México , Pessoa de Meia-Idade , Experimentação Humana não Terapêutica , Valores de Referência , Equivalência Terapêutica

RESUMO

BACKGROUND: Omeprazole is a proton-pump inhibitor that acts to reduce acid secretion in the stomach and is used for treating various acid-related gastrointestinal disorders. There are several generic formulations of omeprazole available in Mexico; however, a literature search failed to identify published data concerning the bioavailability of these formulations in the Mexican population. OBJECTIVE: The aim of this study was to compare the bioavailability of 2 oral formulations of omeprazole 20-mg capsules, marketed for use in Mexico, in healthy volunteers: Inhibitron (test formulation) and LosecA 20 mg (reference formulation). METHODS: This study used a single-dose, open-label, randomized sequence, 2 x 2 crossover (2 administration periods x 2 treatments) design to compare the 2 formulations. Eligible subjects were healthy adult Mexican volunteers of both sexes. Subjects were randomly assigned in a 1:1 ratio to receive a single 20-mg dose of the test formulation followed by the reference formulation, or vice versa, with a 7-day washout period between administration periods. After a 12-hour (overnight) fast, subjects received a single, 20-mg dose of the corresponding formulation. Plasma samples were obtained over a 12-hour period after administration. Plasma omeprazole concentrations were analyzed by a nonstereospecific high-performance liquid chromatography method. For analysis of pharmacokinetic properties, including C(max), AUC from time 0 (baseline) to time t (AUC(0-t)), and AUC from baseline to infinity (AUC(0-infinity)), blood samples were drawn at baseline and 0.17, 0.33, 0.50, 0.75, 1, 1.25, 1.50, 1.75, 2, 2.50, 3, 4, 6, 8, and 12 hours after administration. The formulations were considered bioequivalent if the natural log (ln)-transformed ratios of C(max) and AUC were within the predetermined equivalence range of 80% to 125%, and if P

Assuntos

Inibidores Enzimáticos/administração & dosagem , Omeprazol/administração & dosagem , Administração Oral , Adulto , Disponibilidade Biológica , Cromatografia Líquida de Alta Pressão , Estudos Cross-Over , Relação Dose-Resposta a Droga , Tolerância a Medicamentos , Inibidores Enzimáticos/farmacocinética , Feminino , Seguimentos , Refluxo Gastroesofágico/sangue , Refluxo Gastroesofágico/tratamento farmacológico , Humanos , Masculino , México , Omeprazol/farmacocinética , Valores de Referência

RESUMO

Despite steady progress in therapeutics of liver disease, portal systemic encephalopathy remains to be a great challenge for clinicians because of the heterogeneity of neuropsychiatric symptoms, multiple risk factors and complexity on achieving a sustained response. We aimed to evaluate the efficacy of L-Ornithin, L-Aspartate versus lactulose in Mexican patients with hyperammonemic hepatic encephalopathy. A total of 20 patients were randomly allocated to receive either lactulose(n = 10) or L-ornithine - L-aspartate (n = 10) for 2 weeks. At baseline, patients of both groups were comparable in age (64 +/- 7 versus 60 +/- 6) and degree of hepatic failure according to the Child-Pugh scale (9.2 +/- 1.3 versus 9.2 +/- 1.1). A significant decrease in ammonia levels was observed both in the lactulose group (120.4 +/- 8.1 versus 91.4 +/- 10, p < 0.05) and in the LOLA group (141.6 +/- 9.1 versus 96.9 +/- 9.3, p < 0.05). Moreover, in patients who received LOLA a significant improvement was observed in mental status (1.0 +/- 0.14 versus 0.4 +/- 0.16, p < 0.05), Number Connection Test (184 +/- 43 versus 88 +/- 7, p < 0.05), asterixis (14.6 +/- 2.8 versus 6.7 +/- 1.5, p < 0.05), as well as EEG findings (6.8 +/- 0.6 versus 8.1 +/- 0.2 cycles per second, p < 0.05). Compliance with study medications was similar between the lactulose group (94%) and the LOLA group (100%). No serious adverse events were reported in the two groups; however, in the lactulose group an increase in the number of weekly defecations was reported, as well as a higher incidence of abdominal pain or flatulence. Finally, both patient groups reported an improvement in the Visual Analogue Scale for EuroQol index (51.1 +/- 24.1 versus 61.5 +/- 15.8, p < 0.05, in the lactulose group; 56.5 +/- 24.5 versus 70 +/- 19.4, p < 0.05, in the LOLA group). In conclusion, oral administration of lactulose or L-ornithine - L-aspartate to Mexican patients with cirrhosis and hyperammonemic encephalopathy significantly reduced serum ammonia levels in study groups and additionally improved mental status parameters, number connection test, asterixis scores, and EEG activity in the group receiving L-ornithine-L-aspartate.

Assuntos

Dipeptídeos/uso terapêutico , Fármacos Gastrointestinais/uso terapêutico , Encefalopatia Hepática/tratamento farmacológico , Hiperamonemia/tratamento farmacológico , Lactulose/uso terapêutico , Administração Oral , Cognição , Dipeptídeos/administração & dosagem , Eletroencefalografia , Feminino , Encefalopatia Hepática/complicações , Humanos , Hiperamonemia/complicações , Lactulose/administração & dosagem , Cirrose Hepática/complicações , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos

RESUMO

The role of hepatitis C virus (HCV) is well established in the development of chronic hepatitis, cirrhosis and hepatic carcinoma, as well as in mixed type II cryoglobulinemia, membranoproliferative glomerulonephritis(MPGN) and porphyria cutanea tarda (PCT). Increasing evidence has been reported of a close association of HCV infection with autoimmune and hematological processes, mainly cytopenias and lymphoproliferative disorders such as B cell non-Hodgkin's lymphoma. We describe the demographic, clinical and histopathological findings of nine patients from the Mexican population with non-Hodgkin's lymphoma and HCV infection.

Assuntos

Hepatite C/complicações , Linfoma não Hodgkin/complicações , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Transfusão de Sangue , Ciclofosfamida/uso terapêutico , Doxorrubicina/uso terapêutico , Feminino , Hepatite C/diagnóstico , Humanos , Linfoma não Hodgkin/diagnóstico , Linfoma não Hodgkin/terapia , Masculino , Pessoa de Meia-Idade , Prednisona/uso terapêutico , Vincristina/uso terapêutico

RESUMO

Hepatic perforation is an unusual complication of woman pregnancy associated with a poor outcome. A comprehensive review of epidemiology, clinical spectrum, diagnostic methods and therapeutic options is presented in this short paper.

Assuntos

Hemorragia Gastrointestinal , Hematoma , Hepatopatias , Ruptura Espontânea/fisiopatologia , Feminino , Hemorragia Gastrointestinal/etiologia , Hemorragia Gastrointestinal/fisiopatologia , Hemorragia Gastrointestinal/terapia , Síndrome HELLP/patologia , Síndrome HELLP/fisiopatologia , Hematoma/complicações , Hematoma/fisiopatologia , Humanos , Hepatopatias/patologia , Hepatopatias/fisiopatologia , Hepatopatias/terapia , Gravidez , Ruptura Espontânea/etiologia , Ruptura Espontânea/terapia

RESUMO

OBJECTIVE: To evaluate the frequency of hepatobiliary diseases and the clinical manifestations in patients with HIV treated with non highly active anti-retroviral therapy. METHODS: Seven hundred clinical records of patients with HIV infection who entered the Instituto Nacional de Ciencias Médicas y de la Nutrición Salvador Zubirán from January 1987 to December 1996 were reviewed. All patients with alterations associated to hepatobiliary disease and/or liver function tests derangement throughout the clinical development of their disease were included. Demographic variables, date of diagnosis and clinical stage of the disease, as well as the presentation forms, diagnostic approach and image studies were analyzed. RESULTS: One hundred and sixty-one patients (22.8%) with hepatobiliary manifestations were found. The average time between the HIV diagnosis and the presentation of hepatic manifestations was 2-12 years. The majority of patients 124/161 (77%) did not show clinical signs of liver damage. The diagnostic suspicion was established by the presence of alkaline phosphatase above normal in 29% and alkaline phosphatase plus aminotransferases above normal in 45%. Hepatomegaly and jaundice were present in 18% and 4% of the patients, respectively. The most frequent ultrasonographic diagnosis were hepatomegaly (40%) and steatosis (30%). Liver biopsies were performed in 85 (51%) of the patients. The main histologic diagnoses were granulomatous hepatitis (29%), steatosis plus granulomatous hepatitis (19.5%), and steatosis alone (14.6%). Microorganisms were isolated in 27.9% being the most frequent Mycobacterium tuberculosis (26.6%), Histoplasma capsulatum (20%), Cytomegalovirus (13.3%), and Mycobacterium avium intracellulare (11%). The HBsAg was positive in 21 of the 69 patients (30.4%). CONCLUSIONS: The clinical presentation was asymptomatic in most of cases and the main etiology could be explained by the presence of associated infections, granulomatoses and liver steatosis.

Assuntos

Terapia Antirretroviral de Alta Atividade , Doenças Biliares/epidemiologia , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , Hepatopatias/epidemiologia , Doenças Biliares/diagnóstico por imagem , Doenças Biliares/microbiologia , Infecções por Citomegalovirus/epidemiologia , Feminino , Histoplasma , Histoplasmose/epidemiologia , Humanos , Hepatopatias/diagnóstico por imagem , Hepatopatias/microbiologia , Masculino , Infecções por Mycobacterium/epidemiologia , Infecção por Mycobacterium avium-intracellulare/epidemiologia , Mycobacterium tuberculosis , Estudos Retrospectivos , Ultrassonografia

RESUMO

Despite steady progress in antiviral treatment for patients with chronic hepatitis C virus (HCV), many patients still have detectable serum HCV RNA levels by the end of interferon-based treatment and are known as virological non-responders. Re-treatment of these patients not responding to previous therapy remains challenging. Studies of the dynamics of the HCV population show a marked decline in new cases since 1996; however, the relative proportion of non-responders is expected to increase over time and, similarly, the number of patients eligible for first-line treatment is expected to decrease. The current standard of care for treatment involves the use of pegylated interferons in combination with ribavirin. However, many difficult-to-treat groups still have low response rates. Newer combinations are being investigated to optimize chances of attaining a sustained response in these groups: one such triple therapy regimen is peginterferon alfa-2a, ribavirin and thymalfasin, which was given to 23 previously non-responder patients. Viral response was 60.8% at week 12 and 47.8% at week 24. These preliminary results encourage further evaluation of this promising combination.

Assuntos

Antivirais/uso terapêutico , Hepatite C Crônica/tratamento farmacológico , Interferon-alfa/uso terapêutico , Polietilenoglicóis/uso terapêutico , Ribavirina/uso terapêutico , Timosina/análogos & derivados , Adulto , Quimioterapia Combinada , Feminino , Hepacivirus/efeitos dos fármacos , Hepacivirus/genética , Hepacivirus/crescimento & desenvolvimento , Hepatite C Crônica/genética , Humanos , Interferon alfa-2 , Masculino , México , Pessoa de Meia-Idade , Projetos Piloto , RNA Viral/sangue , Proteínas Recombinantes , Timalfasina , Timosina/uso terapêutico , Fatores de Tempo , Falha de Tratamento , Resultado do Tratamento , Carga Viral , Replicação Viral/efeitos dos fármacos

RESUMO

Despite steady progress in antiviral treatment for patients with chronic hepatitis C virus(HCV), many patients still have detectable serum HCV RNA levels by the end of interferon-based treatment and are known as virological non-responders. Re-treatment of these patients not responding to previous therapy remains challenging. Studies of the dynamics of the HCV population show a marked decline in new cases since 1996; however, the relative proportion of non-responders is expected to increase over time and, similarly, the number of patients eligible for first-line treatment is expected to decrease. The current standard of care for treatment involves the use of pegylated interferons in combination with ribavirin. However, many difficult-to-treat groups still have low response rates. Newer combinations are being investigated to optimize chances of attaining a sustained response in these groups: one such triple therapy regimen is peginterferon alfa-2a, ribavirin and thymalfasin, which was given to 23 previously non-responder patients. Viral response was 60.8% at week 12 and 47.8% at week 24. These preliminary results encourage further evaluation of this promising combination.

Assuntos

Adjuvantes Imunológicos/administração & dosagem , Antivirais/administração & dosagem , Hepatite C Crônica/tratamento farmacológico , Interferon-alfa/administração & dosagem , Polietilenoglicóis/administração & dosagem , Ribavirina/administração & dosagem , Timosina/análogos & derivados , Timosina/administração & dosagem , Quimioterapia Combinada , Humanos , Interferon alfa-2 , Interferons/administração & dosagem , Projetos Piloto , Proteínas Recombinantes , Timalfasina , Fatores de Tempo , Falha de Tratamento

RESUMO

The current criteria to confirm the absence of therapeutic response to HCV is based on the viral findings. Lack of response is defined as the failure to achieve a negative serological response to the virus in peripheral blood (serum or plasma) after 12 weeks of treatment with interferon alpha (2a or 2b), or 24 weeks of treatment with IFN and ribavirin. Up to 60% of patients treated with standard IFN alpha and ribavirin are considered non-responders. According to viral genotype, figures are still worse in the group with genotype 1. Recently, the use of pegylated interferon allowed the reduction of the number of non-responding patients. The investigators propose different approaches in the search for better therapeutic strategies. The most effective of them all are the addition of ribavirin to the therapeutic scheme and the use of pegylated interferon which greatly increased the number of responders. Nevertheless, there are still many patients who are resistant to therapy. These are the proposed therapeutic alternatives for non-respondent patients: 1. Another tretment cycle with standard IFN and ribavirin (low probability) 2. Another treatment cycle with pegylated IFN and ribavirin. 3. Another treatment cycle with IFN, ribavirin and amantadine. 4. Another treatment cycle with IFN, ribavirin and timosine. 5. Other antiviral agents. It's important to clarify that "real non-responders" are those patients who remain positive in the viral load tests after 12-24 months of treatment. On the other hand, patients who "escape from treatment" or those with "recurrence" are not real non-responders, compared to those who are negative after 12-24 weeks of treatment.

Assuntos

Hepatite C/tratamento farmacológico , Antivirais/uso terapêutico , Humanos , Interferons/uso terapêutico , Recidiva , Ribavirina/uso terapêutico

Assuntos

Hepacivirus , Linfoma não Hodgkin

RESUMO

The clinical suspicion of hereditary spherocytosis (HS) must be confirmed at the clinical laboratory. The osotic fragility test (OFT) and the autohemolysis test (AHT) are the worlwide accepted assays to establish a definitive diagnosis of HS; however, they have some disadvantages. We describe herein our experience with the cryohemolysis test (CHT) as a tool to confirm the HS diagnosis. We included four groups of subjects, namely, patients with clinical HS, patients with mechanical heart valve prosthesis, malignant hematological diseases and healthy blood donors. CHT was carried out in all the groups, while OFT and AHT only in the HS patients and healthy individuals. OFT and AHT were performed according to previously described techniques. CHT was performed using red blood cells incubated in a hypertonic solution, preheated for 10 min and then tranferred to an ice bath for an additional 10 min. The resulting cryohemolysis was determined mesuring the free hemoglobin in the sample. There were no differences among the groups in terms of general characteristics. All HS suspicious patients had a positive OFT and AHT. CHT was positive in all patients from the HS group but in none of the subjects from the control groups (p<0.001). We found that CHT is a faster and easier-to-perform assay compared with OFT and AHT. Moreover, using CHT, the zone between normal and abnormal results is wider than OFT or AHT. We propose 0.7 to 11 percent hemolysis as reference values for CHT

Assuntos

Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Doadores de Sangue , Congelamento , Hemólise , Fragilidade Osmótica , Sensibilidade e Especificidade , Solução Salina Hipertônica/farmacologia , Esferócitos/efeitos dos fármacos , Esferocitose Hereditária/sangue , Esferocitose Hereditária/diagnóstico

RESUMO

Los anti-inflamatorios no esteroideos son fármacos ampliamente utilizados en la práctica clínica. Debido a la extensa gama de efectos secundarios asociados a su uso en este artículo nos enfocamos a describir las lesiones gástricas, revisando su fisiopatogenia, su prevalencia e incidencia, así como sus manifestaciones clínicas, factores predisponentes, tratamiento y profilaxis

Assuntos

Humanos , Anti-Inflamatórios não Esteroides/efeitos adversos , Anti-Inflamatórios não Esteroides/farmacologia , Prostaglandinas , Gastropatias/induzido quimicamente

RESUMO

Objetivos. 1) Evaluar las alteraciones bioquímicas, renales, histológicas y hemodinámicas esplácnicas y sistémicas que ocurren en la cirrosis biliar inducida por ligadura del conducto colédoco en ratas; y 2) conocer la relación cronológica entre el inicio de hipertensión portal, disminución de excreción urinaria de sodio y activación del sistema renina-angiotensina. Metodología. Se estudiaron 127 ratas macho de la cepa Wistar con ligadura del conducto colédoco a diferentes periodos de tiempo (una, dos, tres y cuatro semanas de obstrucción) y se compararon con 30 ratas controles. Resultados. La presión portal aumentó significativamante a partir de la primera semana de obstrucción (11.7 ñ 1.5 vs 7.8 ñ 1.5 mmHg, p < 0.05) mientras que la presión arterial media se mantuvo estable hasta la cuarta semana en que presentó una ligera disminución no significativa (91.3 ñ 6.6 vs 96.1 ñ 8.6 mmHg) en ratas controles. Se observó una disminución significativa en la excreción urinaria de sodio a partir de la primera semana de obstrucción (1.1 ñ 0.5 mEq/24 h) comparado con el grupo de las ratas controles (2.3 ñ 0.6). También se observó hiperreninemia desde la primera semana (5.1 ñ 2 vs 2.4 ñ 1.3 ng Ang I/mL/h, p < 0.05) e hiperaldosteronismo desde la segunda semana (103 ñ 46 vs 25 ñ 8.8 ng/24 h, p < 0.05) comparados con el grupo control. Conclusión. El inicio de la hipertensión portal a la primera semana de obstrucción biliar se relaciona cronológicamente con el inicio de la disminución de la excreción urinaria de sodio y con la hiperreninemia y el hiperaldosteronismo. Este modelo experimental de cirrosis podría ser útil para evaluar el efecto de diversas maniobras terapéuticas que tengan como objetivo detener o prevenir el proceso cirrógeno, incluyendo las alteraciones en la excreción urinaria de sodio

Assuntos

Animais , Masculino , Ratos , Ascite/etiologia , Hipertensão Portal/etiologia , Cirrose Hepática Experimental , Ratos Wistar , Sistema Renina-Angiotensina , Sódio/urina

RESUMO

Objetivo. Conocer si la relación cobre/zinc (cobre elevado, zinc bajo) se encuentra aumentada en pacientes con neoplasias malignas hematológicas comparada con sujetos controles sanos de edad y sexo similares. Metodología. Se estudiaron 44 pacientes con neoplasias hemato-concológicas de reciente diagnóstico, sin tratamiento previo: 17 linfomas (11 no-Hodgkin), 15 con leucemia aguda (10 mieloblásticas) y 12 con leucemia crónica (8 granulocíticas). También se incluyeron 95 sujetos controles sanos. Se utizó un espectrofotómetro de absorción atómica (Perkin Elmer modelo 2380) para la cuantificación de los niveles séricos de cobre y zinc. Resultados. Los niveles séricos de cobre (µg/dL) fueron significativamente menores en los sujetos controles(54.4 ñ 8.9, p< 0.05), en comparación con los pacientes con linfoma (93.7 ñ 37.5), con leucemia aguda (80.6 ñ 44.6) y con leucemia crónica (95.7 ñ 28.9) mientras que los niveles séricos de zinc (µg/dL) resultaron significativamente mayores en sujetos controles (100.4 ñ 14, p< 0.05) en comparación con los pacientes con linfoma (77.2 ñ 22.6), leucemia aguda (66 ñ 15.6) o leucemia crónica (74.8 ñ 14.7). La relación cobre/zinc resultó ser significativamente más baja en sujetos controles (0.54 ñ 0.13, p< 0.05) que en pacientes con linfoma (1.21 ñ 0.5), leucemia aguda (1.22 ñ 0.7) o leucemia crónica (1.28 ñ 0.4). Veintitrés pacientes falleciron durante el seguimiento (media de 13 meses) observándose que sus niveles séricos de zinc fueron significativamente más bajos (68 ñ 28) que en los pacientes que sobrevivieron (76 ñ 15, p< 0.05). Conclusión. La relación sobre/zinc se encuentra significativamente elevada en pacientes con neoplasias malignas hematológicas

Assuntos

Masculino , Cobre/sangue , Leucemia Mielogênica Crônica BCR-ABL Positiva/sangue , Leucemia Mieloide Aguda/sangue , Linfoma não Hodgkin/sangue , Linfoma/sangue , Oligoelementos/análise , Oligoelementos/sangue , Zinco/sangue , Zinco/deficiência

RESUMO

Antecedentes y métodos. Recientemente se ha informado una posible asociación entre la infección por virus de hepatitis C (VHC) y las glomérulonefritis membranoproliferativa (GNMP) y membranosa. La fisipatogenia de esta entidad parece estar mediada por depósito de complejos inmunes en los glomérulos. El objetivo de este informe es describir las característias clínicas, de laboratorio e histopatológicas de tres pacientes con infección crónica por VHC, sin infección por virus de la hepatitis B ni enfermedades autoinmunes, y con evidencia de enfermedad glomerular. Resultados. Todos los pacientes presentaron estigmas de hepatopatía crónica, ascitis y edema periférico, y presión arterial normal. Los resultados de laboratorio no mostraron alteraciones significativas en pruebas de función hepática y en las cifras de elementos azoados; los tres casos presentaron hematuria microscópica, hipoalbuminemia y albuminuria de grado variable, sin hipercolesterolemia y factor reumatoide positivo. Sólo un paciente tuvo anticuerpos antinucleares y anticuerpos antimitocondriales positivos a títulos bajos, y otro más presentó niveles bajos de C3 y C4. En los tres casos, las biopsias de riñón fueron interpretadas como glomérulonefritis membranoproliferativa tipo I, y las de hígado como cirrosis. Conclusiones. Las evidencias presentadas apoyan la asociación de la enfermedad crónica por virus de la hepatitis C y la glomérulonefritis membranoproliferativa. Es necesario realizar otros estudios para establecer más firmemente la asociación, fisiopatogenia y causalidad entre estas entidades

Assuntos

Adulto , Humanos , Masculino , Feminino , Biópsia/estatística & dados numéricos , Cirrose Hepática/patologia , Glomerulonefrite Membranoproliferativa/diagnóstico , Glomerulonefrite Membranoproliferativa/patologia , Hepatite C/diagnóstico , Hepatite C/imunologia , Hepatite C/patologia

Assuntos

Humanos , Hipertensão Portal/diagnóstico , Hipertensão Portal/fisiopatologia